Jen-Pharma Products Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.40 M
- Company Age 29 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 19.23%
- Profit Growth -122.64%
- Ebitda -11.75%
- Net Worth -3.03%
- Total Assets -0.01%
About Jen-Pharma Products
Jen-Pharma Products Private Limited (JPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 August 1995 and has a history of 29 years and six months. Its registered office is in Raigarh, Maharashtra, India.
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.40 M, as per Ministry of Corporate Affairs (MCA) records.
Mahesh Dalal, Krishnakant Parikh, and Nijen Desai serve as directors at the Company.
Company Details
-
Location
Raigarh, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH1995PTC091446
-
Company No.
091446
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Aug 1995
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Jen-Pharma Products?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahesh Dalal
|
Director | 07-Aug-1995 | Current |
|
Krishnakant Parikh
|
Director | 07-Aug-1995 | Current |
|
Nijen Desai
|
Director | 07-Aug-1995 | Current |
Financial Performance of Jen-Pharma Products.
Jen-Pharma Products Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 19.23% increase. The company also saw a substantial fall in profitability, with a 122.64% decrease in profit. The company's net worth dipped by a decrease of 3.03%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jen-Pharma Products?
In 2018, Jen-Pharma Products had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Elcid Investments LimitedMahesh Dalal is a mutual person
-
Enkay Superstructures Private LimitedKrishnakant Parikh is a mutual person
-
Madhu Management Private Limited
Krishnakant Parikh is a mutual person
-
Enkay Trading Private Limited
Krishnakant Parikh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jen-Pharma Products?
Unlock and access historical data on people associated with Jen-Pharma Products, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jen-Pharma Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jen-Pharma Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
